Paper Details

  1. Home
  2. Paper Details

Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension.

Author: NishimuraMasaharu, OhiraHiroshi, SatoTakahiro, TsujinoIchizo, WatanabeTaku, YamadaAsuka, YamashitaYu

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

Two WHO-FC IV PoPH patients were successfully treated with a combination of ambrisentan and tadalafil, suggesting this oral vasodilator therapy may be a safe and effective option for selected PoPH patients with severe disease.
Paper Details　
Original Abstract of the Article :
Intravenous epoprostenol is recommended for World Health Organization functional class (WHO-FC) IV patients with pulmonary arterial hypertension (PAH) in the latest guidelines. However, in portopulmonary hypertension (PoPH) patients, advanced liver dysfunction and/or thrombocytopenia often makes the...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243157/

データ提供：米国国立医学図書館（NLM）

Abrisentan-Tadalafil Combination for Progressive Portopulmonary Hypertension

Portopulmonary hypertension (PoPH), a rare and life-threatening condition, is often difficult to treat. This study investigates the use of a combination of two oral vasodilators, ambrisentan and tadalafil, for treating patients with advanced PoPH. The researchers report on two patients with severe PoPH who were successfully treated with this combination therapy. Their findings offer a glimmer of hope for patients with this challenging condition.

Navigating the PoPH Desert

The study highlights the potential of ambrisentan-tadalafil combination therapy for patients with advanced PoPH, especially those who are unable to receive intravenous epoprostenol, the standard treatment. This approach, like finding a safe passage through a treacherous desert, could offer a valuable alternative for patients with limited treatment options. The study's success in treating two patients with severe PoPH suggests that this combination therapy could be a viable option for a broader range of patients.

A New Oasis of Hope for PoPH Patients

This study provides valuable insights into the potential of ambrisentan-tadalafil combination therapy for patients with advanced PoPH. The findings offer hope for a group of patients who often face limited treatment options. This research, like a shimmering oasis in the desert of PoPH, suggests that new and innovative approaches to treatment are constantly emerging, offering hope for patients who need it most.

Dr. Camel's Conclusion

This study underscores the importance of exploring alternative treatment options for patients with rare and challenging conditions like PoPH. The findings suggest that ambrisentan-tadalafil combination therapy could be a viable option for patients who are unable to receive intravenous epoprostenol. This study is a reminder that in the vast and ever-evolving desert of medicine, we must continuously seek out new and innovative solutions to improve the lives of our patients.
Date :
  1. Date Completed 2014-11-27
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

25429321

DOI: Digital Object Identifier

PMC4243157

Related Literature

Article Analysis
・Effects of ambrisentan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.